MSB Docs yesterday announced eight pharma sector customer wins, the company notified in a statement.
Ithaca, NY, the US-based Contract Research and Development Organisation (CRDO) is using MSB Docs solutions for 21 CFR Part 11 contracts between CRO and pharma companies. The organisation offers development and testing services to the medical device, pharma and consumer product industries. Its area of expertise includes biocompatibility, antimicrobial, novel coating, small molecule, peptide and protein applications, said the statement.
It also mentioned that Irvine, California, the US-based lifesciences platform powering next-generation trials to develop safe and efficacious treatments is also using MSB Docs solutions for 21 CFR Part 11 contracts between CRO and pharma companies. The company accelerates the adoption of digital health in research by providing a low barrier of entry analytics as a service with its big data platform.
Murray, the US-based CRO organisation has leveraged MSB Docs’ superior domain expertise for the pharma sector with the integration of e-signature and digital smart document solutions.
The statement noted that Toronto, Canada-based leader in clinical research is using MSB Docs solutions for 21 CFR Part 11 contracts between CRO and pharma companies. The organisation works with the industry and healthcare community to advance therapeutic treatment options. It has completed over 200 phase-II, III and IV research projects since inception with more than 700 physicians serving approximately three million people.
It added that New York, the US-based e-clinical, pharmacovigilance, and commercialisation technologies and solutions are integrating MSB Docs with their software for e-signing. The company undertakes over 400,000 projects per year. It has more than 6,000 full-time employees, a network of over 10,000 certified linguists and subject-area specialists and offices in more than 100 cities around the globe.
London, UK-based biopharma organisation has integrated MSB Docs in the process of developing and commercialising new therapies for oncology and rare diseases. Its clinical research associates now spend more time on their experiments and less time chasing paper, the statement further stated.
Osaka, Japan-based pharma giant with MSB Docs integration is improving efficiency and turnaround time of product development lifecycle. Its management of sensitive and confidential documents in the entire process from R&D to clinical testing to launching a new drug and storage for regulatory compliances has been transformed, it said.
Buenos Aires, Argentina-based scientific and site management organisation for paediatric infectious diseases and immunology is improving productivity, growth, quality and client experience across sponsors, CROs and investigators in all aspects of clinical trials. The vast number of daily contracts and agreements have ditched the paper-intensive task resulting in significant improvement in the contract preparation and completion rates, approval process, and the ability to forecast and execute, concluded the statement.